Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
about
Advances in antibiotic therapy in the critically illExtra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technologyClinical pharmacology of midazolam in neonates and children: effect of disease-a reviewQuantification of perflutren microsphere contrast destruction during transit through an ex vivo extracorporeal membrane oxygenation circuit.Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.Decreased blood product usage during extracorporeal life support with reduced circuit volumes.Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration.Patients with hematologic malignancies have many reasons to die during extracorporeal membrane oxygenationASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO.The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort studyHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort studyProtein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study.Designing drug regimens for special intensive care unit populations.Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case seriesTrough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation.A review of emergency cardiopulmonary bypass for severe poisoning by cardiotoxic drugs.Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenationPharmacokinetics of Peramivir in an Adolescent Patient Receiving Continuous Venovenous Hemodiafiltration.Is hyperoxaemia helping or hurting patients during extracorporeal membrane oxygenation? Review of a complex problem.Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review.Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation.Medicating patients during extracorporeal membrane oxygenation: the evidence is building.Antithrombin III Doses Rounded to Available Vial Sizes in Critically Ill Pediatric Patients.Extracorporeal respiratory support in adult patients.Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation.Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human bloodMacro- and micronutrient disposition in an ex vivo model of extracorporeal membrane oxygenationIn vitro clearance of intravenous acetaminophen in extracorporeal membrane oxygenation.Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation.High-Dose Sedation and Analgesia During Extracorporeal Membrane Oxygenation: A Focus on the Adjunctive Use of Ketamine.Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.Nurse-driven analgesia and sedation in pediatric patients with univentricular hearts requiring extracorporeal life support after first-stage palliation surgery: A pilot study.In vitro effects of an extracorporeal membrane oxygenation circuit on the sequestration of ϵ-aminocaproic acid.Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support.
P2860
Q26749328-DE341510-5AE3-430C-A50D-11AC64934CA8Q26783774-8155830E-1D25-417D-8695-6520259066C3Q27006333-80CF52D0-EFF7-4692-84B7-8D70E9DCE720Q27316284-EE5D8DB5-1E0D-406B-929B-F07D8C06A7F0Q30249512-7B7D3B02-E4BD-4164-AA80-DECBFF9F98A6Q30252935-EDB3EDDC-5874-4C9D-A67C-4D405FC7AD94Q31032098-22778380-6C6D-48F2-9733-0260C28D05DFQ33442897-B33C8173-C706-40B8-9B30-C7FBBA636128Q34178411-6F3EA52A-0684-411E-AE11-F43DDCFC55D5Q34494688-95A842BD-E846-40D3-B95E-5E33F4976A3DQ34630847-82DD84A4-73DA-4401-9D0F-A32334FD230FQ34636783-03C7D4A3-9982-4E51-BC00-51C1DB8CD469Q34894900-D595EB2C-D582-42D1-8DC7-9DF90DF39B55Q34996307-3D0AACDB-34C3-4F4B-B7AD-933B08B0B7C4Q35530267-DFDBCD36-0771-4175-99E5-55158706EEBBQ35544079-82B1B815-DCEC-42B3-8ED9-D2F50213D2BFQ35953787-FBECC24E-0E94-4D56-B4AA-1169BA6F8887Q36257532-50A11546-FBDA-4542-AE70-7811B75651BAQ36621834-54ED8731-6407-458C-AECF-B99A83F64A23Q36928231-5A18C8CF-10E2-449F-8330-A66120ADA12DQ37686604-DB4742F8-07FB-49C0-A0AA-95D1D87FDB4CQ38074386-B01703BA-D3D5-40E5-81F0-9682229D1DBEQ38230538-EE4E10FE-8B00-4705-9376-F9C62F582904Q38374584-90E3CAA2-3285-4515-89EE-ECCB00A9491BQ38751931-16FB48C2-2F32-4B1C-8203-EBC16C010116Q38837353-96F120D6-B5EC-4F8E-B346-FBA1384BBEFCQ39033001-11F8CDB8-8624-4B41-9652-FAFEE659DFB7Q39188586-F0D028E1-946B-4CE5-9D7C-B459E08D77DCQ39197597-23E2D3C7-AD3E-431C-8D87-E4664E391493Q39222269-6EBA6061-B867-49FC-A4F1-E6A4E3DF32E3Q40661074-5E9602C9-4D00-48F2-9FED-9900EF9F2083Q41052029-5818651B-5836-4B93-834C-E3DD33C95173Q42210005-9D09416C-08FD-476A-AE16-F40F398A56EFQ45991016-561EE413-2E8F-471B-B002-D0595C899E4BQ47152342-9FCA3727-2883-4822-9A96-F443C6AB856EQ47591928-D9DA0F2C-6D1A-4DA4-B6A1-87C3813BE13FQ47632337-68F10573-09E2-4A35-82EF-D889A60CE40FQ47732023-4F06093D-8D25-4058-B33B-3B89BD27CD94Q51075997-E21EE31B-A203-4782-ABBA-6F784CC7D123Q51702479-29E726BF-3463-4E21-8773-7975EEB3554D
P2860
Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
@en
type
label
Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
@en
prefLabel
Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
@en
P50
P1476
Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
@en
P2093
John F Fraser
P304
P356
10.1016/J.JCRC.2012.02.013
P577
2012-04-18T00:00:00Z